It reduces appetite and helps control blood sugar levels, which leads to substantial weight loss for many users in clinical trials of FDA-approved products
This approach has become the standard with GLP-1 and GIP receptor agonists because rapid introduction at high doses often leads to nausea, vomiting, or diarrhea severe enough for patients to discontinue treatment
Li Z, Low V, Luga V, Sun J, Earlie E, Parang B, et al
The fix: verify coverage directly
Additional emerging data further support the idea that hormonal status influences both weight loss responsiveness and body composition outcomes during GLP-1 therapy [17], consistent with the mechanistic picture of HRT restoring a metabolic environment that makes GLP-1 receptor agonists more effective
They might not